New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
In order to improve the results of hormonal therapy of gynecologic malignancies by means of medroxyprogesterone acetate two approaches are explored. In the first approach medroxyprogesterone dosage increased up to 400 mg a day, achieved better results in curative as well as adjuvant treatment of advanced or early gynecologic cancers. In the other approach, the combined, simultaneous or successive treatment by means of tamoxifen and medroxyprogesterone was even more successful for these therapeutic purposes compared to monohormonotherapy.
Vanderstappen
D
D
Upjohn N. V., Puurs, Belgium.
Bonte
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone